Ken Griffin Galectin Therapeutics Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.04 - $2.86 $99,756 - $139,854	48,900 Added 359.56%	62,500 $171,000
Q2 2024 Aug 14, 2024	BUY	$2.13 - $4.2 $12,567 - $24,780	5,900 Added 76.62%	13,600 $30,000
Q1 2024 May 15, 2024	BUY	$1.6 - $2.44 $7,040 - $10,736	4,400 Added 133.33%	7,700 $18,000
Q4 2023 Feb 14, 2024	BUY	$1.6 - $2.18 $5,280 - $7,194	3,300 New	3,300 $5,000
Q2 2023 Aug 14, 2023	SELL	$1.32 - $2.08 $10,428 - $16,432	-7,900 Reduced 44.89%	9,700 $13,000
Q1 2023 May 15, 2023	BUY	$1.1 - $2.4 $19,030 - $41,520	17,300 Added 5766.67%	17,600 $36,000
Q4 2022 Feb 14, 2023	BUY	$1.03 - $1.66 $309 - $498	300 New	300 $0

9.57M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $162M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.